PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC

被引：0
|
作者：
Marzia Del Re
Riccardo Marconcini
Giulia Pasquini
Eleonora Rofi
Caterina Vivaldi
Francesco Bloise
Giuliana Restante
Elena Arrigoni
Chiara Caparello
Maria Grazia Bianco
Stefania Crucitta
Iacopo Petrini
Enrico Vasile
Alfredo Falcone
Romano Danesi
机构：
[1] Clinical Pharmacology and Pharmacogenetics Unit,Department of Clinical and Experimental Medicine
[2] University of Pisa,Department of Translational Research and New Technologies in Medicine and Surgery
[3] Medical Oncology Unit,Department of Translational Research and New Technologies in Surgery and Medicine
[4] University of Pisa,undefined
[5] General pathology,undefined
[6] University of Pisa,undefined
来源：
British Journal of Cancer | 2018年 / 118卷
关键词：
PD-L1; exosomes; circulating nucleic acids; immunotherapy; predictive biomarker; pharmacogenetics; nivolumab; pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：820 / 824
页数：4
相关论文
共 50 条
  • [41] Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
    Mishra, Surbhi
    Amatya, Sajeen Bahadur
    Salmi, Sonja
    Koivukangas, Vesa
    Karihtala, Peeter
    Reunanen, Justus
    CANCERS, 2022, 14 (20)
  • [42] Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC)
    Zeng, Tian
    Qin, Qin
    Bian, Zhiheng
    Li, Jianjun
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2019, 47 (01) : 4194 - 4201
  • [43] Association between response to anti-PD-1 treatment and blood soluble PD-L1 and IL-8 changes in patients with NSCLC
    Yi, Ling
    Wang, Xiaojue
    Fu, Siyun
    Yan, Zhuohong
    Ma, Tianyu
    Li, Siqi
    Wei, Panjian
    Zhang, Hongtao
    Wang, Jinghui
    DISCOVER ONCOLOGY, 2023, 14 (01)
  • [44] Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
    Sahni, Sakshi
    Valecha, Gautam
    Sahni, Ankit
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2018, 10 (12)
  • [45] PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma
    Ellebaek, Eva
    Khan, Shawez
    Bastholt, Lars
    Schmidt, Henrik
    Haslund, Charlotte Aaquist
    Donia, Marco
    Svane, Inge Marie
    EUROPEAN JOURNAL OF CANCER, 2024, 198
  • [46] The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
    Peng, Zhi
    Cheng, Siyuan
    Kou, Yan
    Wang, Ziqi
    Jin, Rong
    Hu, Han
    Zhang, Xiaotian
    Gong, Ji-fang
    Li, Jian
    Lu, Ming
    Wang, Xicheng
    Zhou, Jun
    Lu, ZhiHao
    Zhang, Quan
    Tzeng, David T. W.
    Bi, Dongtao
    Tan, Yan
    Shen, Lin
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (10) : 1251 - 1261
  • [47] PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy
    Di Federico, Alessandro
    De Giglio, Andrea
    Parisi, Claudia
    Gelsomino, Francesco
    Ardizzoni, Andrea
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
  • [48] Anti-PD-1 and Anti-PD-L1 Monoclonal Antibodies in People Living with HIV and Cancer
    Lurain, Kathryn
    Ramaswami, Ramya
    Yarchoan, Robert
    Uldrick, Thomas S.
    CURRENT HIV/AIDS REPORTS, 2020, 17 (05) : 547 - 556
  • [49] Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
    Bender, Carolin
    Enk, Alexander
    Gutzmer, Ralf
    Hassel, Jessica C.
    CANCER MEDICINE, 2017, 6 (07): : 1581 - 1586
  • [50] Tissue biomarkers of response to anti-PD-1 immunotherapies in melanoma
    Adam, Julien
    Tomasic, Gorana
    Robert, Caroline
    ANNALES DE PATHOLOGIE, 2017, 37 (01) : 55 - 60
12345